Abstract People with schizophrenia are 3-4 times more likely to die from cardiovascular disease than the general population. Clozapine (CLZ) is the gold standard of treatment for refractory schizophrenia. It has been associated with tachycardia and recent evidence shows individuals prescribed CLZ may develop blood pressure (BP) elevation and hypertension. The purpose of this study was to examine the effects of CLZ on BP and heart rate (HR DSM IV diagnosis of Schizophrenia or Schizoaffective disorder. Primary outcomes were systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR measured 12 weeks before and 24 weeks during CLZ treatment. Eighteen patient records were included in this study. The mean stabilized CLZ dose was 441.7 ± 171.8 mg/day. DBP (t = 1.02, df = 79.5, = 2.00, 0.049) and HR (t = 1.32, df = 355 = -4.61, \ 0.0001) were significantly higher after CLZ initiation. A trend was noted for increase in SBP (p = 0.071). 22 % of patients met criteria for hypertension before CLZ and 67 % during CLZ treatment (Chi Square = 6.25, df = 1, p = 0.0124). No significant changes in weight or renal function occured during CLZ treatment. No patients had evidence of cardiomyopathy. The data suggest CLZ may be associated with a rise in BP and HR. The results of this study support previous literature that found an increase in SBP/DBP regardless of CLZ dose, occurring early in treatment. Due to high risk of cardiovascular morbidity and mortality, more work is needed to determine risk factors and understand the mechanism of action that may cause this side effect.
Introduction
Schizophrenia is a chronic, often disabling illness that affects approximately 24 million worldwide [1] . People with schizophrenia have a shorter life span, between 10 and 25 years less, and are 3-4 times as likely to die from cardiovascular disease than the general population [2] . Many risk factors for cardiovascular disease exist including increased lipid levels, cigarette smoking, sedentary lifestyle, hypertension, and obesity [3] .
Clozapine (CLZ) is considered the gold standard of treatment for people who remain symptomatic despite two adequate trials of other antipsychotic agents [3] . CLZ is the most effective antipsychotic for patients who do not respond to treatment with first or second generation antipsychotics [3, 4] . There are multiple studies which provide evidence of the superiority of CLZ [5] [6] [7] [8] [9] [10] [11] . CLZ has also been associated with longer treatment duration, greater improvement in symptoms, and higher patient and clinician subjective ratings [12, 13] . However, CLZ is often underutilized, in part, due to its side effect profile [14] .
CLZ has a host of side effects associated with its use including some serious cardiovascular effects such as cardiomyopathy, myocarditis, and metabolic syndrome [15, 16] Tachycardia is also known to occur, and recent evidence has shown that individuals prescribed CLZ may develop blood pressure (BP) elevation and hypertension [17] [18] [19] [20] [21] [22] [23] [24] . In this study, we examined BP and heart rate (HR) changes during CLZ treatment.
Methods

Sample and Procedure
Medical records of adult patients between the ages of 18 and 75 years old admitted to an inpatient research unit with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) diagnosis of Schizophrenia or Schizoaffective disorder and initiated on CLZ were reviewed [25] . Forty-eight charts were identified for inclusion. 15 patients were excluded due to missing medical records, 13 because they did not have 24 weeks of follow up after the initiation of CLZ treatment, and two due to unknown CLZ treatment initiation date. Demographic information was collected for all patients. Systolic blood pressure (SBP), diastolic blood pressure (DBP), HR, blood urea nitrogen (BUN), serum creatinine (SCr), glomerular filtration rate (GFR), CLZ dose and blood level, and weight were collected for 12 weeks before and 24 weeks during CLZ treatment. The University of Maryland and State of Maryland Department of Health and Mental Hygiene Institutional Review Boards approved this study.
Statistical Methods
All values for SBP, DBP, HR, weight, BUN, SCr, and GFR were collected and means were analyzed before and after starting CLZ using t tests. Dichotomous variables were compared using Chi Square. Mean values for maximum stabilized CLZ dose, CLZ level, norclozapine level, and total CLZ level were also calculated. The following definitions were used to evaluate BP and HR: Eighth Joint National Committee (JNC8) Guideline for the Management of Hypertension defines hypertension as a SBP reading[140 mm Hg and/or DBP reading of[90 mm Hg on a minimum of two separate occasions [26] . The American Heart Association (AHA) defines tachycardia as a HR [100 beats per minute [27] .
Results
There were 18 patient records included in this study. The mean age of the group was 36.4 ± 12.5 years with the majority, male, Caucasian and cigarette smoking (Table 1) . Two patients were diagnosed with hypertension.
From pre to post BP and HR data collected associated with CLZ treatment, there was a significant increase in DBP (t = 1.45, df = 79.5 = -2.00, 0.049) and HR (t = 1.32, df = 355 = -4.61, \ 0.0001). There was also a trend noted to an increase in SBP (Table 2 ). In the 12 weeks prior to CLZ treatment, 4/18 (22 %) patients met criteria for , df = 1, p = 0.0046). In the two patients who had documented history of an ICD9 code diagnosis of hypertension, neither met hypertension criteria in the evaluation prior to treatment. However, one became hypertensive during treatment with CLZ, despite receiving antihypertensive medications. Table 3 characterizes renal function and weight before and during CLZ treatment. No significant differences were noted in these variables. None of the patients had evidence of cardiomyopathy.
Discussion
Overall the data suggest CLZ may be associated with an increase in DBP, SBP, and HR. The number of patients meeting the definition of hypertension tripled and the number of patients who met the definition of tachycardia more than doubled during CLZ treatment. The results are consistent with previous studies that found an increase in SBP/DBP regardless of CLZ dose and occurred early in treatment. For example, Henderson et al. noted elevations in BP developed relatively soon after initiation and increased to the hypertensive range after 6 months [28] . Additionally, a significant positive correlation between weight gain and the increase in SBP was described [28] . Woo et al. compared CLZ with olanzapine and up to 16.7 % of CLZ patients met criteria for hypertension over that time period, compared with 5.4 % on olanzapine [29] . In a small study by Oyewumi et al., autonomic dysfunction during CLZ dose titration was demonstrated [30] . Of note, a weak correlation between clozapine:norclozapine ratio and BP elevation was found [30] . We did not find an association between increased BP and HR and renal function or weight in the study, suggesting there may a mechanism of BP elevation independent of obesity. It has been suggested that the mechanism of hypertension may partly involve an autonomic dysfunction due to adrenergic hyperactivity of CLZ [17, 31] The response of the hypertension to a2 adrenoceptor blockers further supports the latter [17, 32] . CLZ has an affinity for a2 adrenoreceptors that is 18 times higher than olanzapine [33] . The antagonistic effect of CLZ on a2 receptors resulting in prolonged release of noradrenaline from synaptic reuptake has been surmised to cause this elevation in BP [29, [33] [34] [35] . It is noteworthy that the presentation of CLZ induced hypertension has been very similar to pheochromocytoma, with elevated BP and urinary catecholamines [32] . We did not examine urinary catecholamines in this study. Our group is conducting a pilot study to examine the impact of CLZ on renal dopamine receptors which also may contribute. We have reported that the germline deletion of the dopamine D4 receptor in mice causes hypertension [36] . CLZ has higher affinity for the D4 receptor than for the other dopamine receptors, including the D2 receptor [37] . Nevertheless, germline deletion of the dopamine D2 receptor in mice also causes hypertension [38] .
Our small pilot study is limited in that it is a retrospective chart review and, therefore, limited to the information documented in the patient's medical record. Also, some variables collected were not present in all patients, such as GFR. Factors like caffeine use, intensity of cigarette smoking, exercise habits, and sodium intake may have contributed to the increases in BP and HR that we were unable to measure. Due to the high risk of cardiovascular morbidity and mortality in this population, more work is needed to determine risk factors and understand the mechanism of action that may cause this side effect. 
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